Castle Biosciences (Castle Biosciences) EV-to-Revenue

: 1.43 (As of Today)

View and export this data going back to 2019. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Castle Biosciences's enterprise value is $313.2 Mil. Castle Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $219.8 Mil. Therefore, Castle Biosciences's EV-to-Revenue for today is 1.43.

The historical rank and industry rank for Castle Biosciences's EV-to-Revenue or its related term are showing as below:

CSTL' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.61 Med: 7.47 Max: 25.25
Current: 1.43

During the past 7 years, the highest EV-to-Revenue of Castle Biosciences was 25.25. The lowest was 0.61. And the median was 7.47.

CSTL's EV-to-Revenue is ranked better than
74.89% of 227 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.03 vs CSTL: 1.43

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-23), Castle Biosciences's stock price is $20.06. Castle Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $8.19. Therefore, Castle Biosciences's PS Ratio for today is 2.45.

Castle Biosciences EV-to-Revenue Historical Data

The historical data trend for Castle Biosciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Castle Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

9.93

20.05

8.15

2.77

1.66

Castle Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															2.77	2.54	0.93	1.24	1.66

Competitive Comparison

For the Diagnostics & Research subindustry, Castle Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Castle Biosciences EV-to-Revenue Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Castle Biosciences's EV-to-Revenue falls into.

Castle Biosciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Castle Biosciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	313.218	/	219.788
	=	1.43

Castle Biosciences's current Enterprise Value is $313.2 Mil.
Castle Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $219.8 Mil.

Castle Biosciences (NAS:CSTL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Castle Biosciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	20.06	/	8.194
	=	2.45

Castle Biosciences's share price for today is $20.06.
Castle Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.19.

Castle Biosciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Castle Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Castle Biosciences (Castle Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Castle Biosciences Inc (NAS:CSTL) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 S. Friendswood Drive, Suite 401, Friendswood, TX, USA, 77546

Website

https://www.castlebiosciences.com

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Executives

Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Derek J Maetzold	director, 10 percent owner, officer: Pres. & Chief Exec. Officer	820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Ellen Goldberg	director	C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Tiffany Olson	director	C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Kristen M Oelschlager	officer: Chief Operating Officer	C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Bernhard E. Spiess	officer: Chief Operating Officer	C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Kim Caple	director	C/O BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Frank Stokes	officer: Chief Financial Officer	C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Tobin W Juvenal	officer: Chief Commercial Officer	C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
David S Kabakoff	director, 10 percent owner	C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Cook Joseph C. Iii	director, 10 percent owner	C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, STE. 201, FRIENDSWOOD TX 77546
Mara G. Aspinall	director	7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Bonnie H Anderson	director	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mgc Venture Partners 2013 Gp, Llc	10 percent owner	C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203
Mgc Venture Partners 2013, L.p.	10 percent owner	C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203